<?xml version="1.0" encoding="UTF-8"?><Articles><Article><id>452</id><JournalTitle>BENEFIT-RISK ASSESSMENT OF CALCITONIN SALMON USING POST-APPROVAL SURVEILLANCE DATA TO CONCLUDE THE SAFETY OF CALCITONIN NASAL SPRAY</JournalTitle><Abstract>Calcitonin salmon is a single chain polypeptide containing 32 amino-acid residues, which is used for the treatment of
postmenopausal osteoporosis, hypercalcaemia, Pagetâ€™s disease, bone metastases, phantom limb pain, and spinal stenosis.
However, Calcitonin-containing medicines are recommended for short-term treatment as the long-term use is associated with an
increased risk of cancer. The primary aim of the study was conducted benefit-risk assessment of calcitonin salmon using postapproval surveillance data to conclude the safety of calcitonin nasal spray. Calcitonin (salmon) nasal solution is more potent
and longer acting, as it exhibits greater affinity to receptor binding sites than calcitonin from mammalian species, including the
synthetic human calcitonin. In terms of bioactivity, the potency of calcitonin (salmon) nasal solution was found to be about half
that of the drug given by intramuscular or subcutaneous injection. Calcitonin (salmon) was non-mutagenic on Salmonella
typhimurium (5 strains), Escherichia coli (2 strains) and mammalian V79 cells of the Chinese Hamster. Calcitonin (salmon) is
effective in postmenopausal osteoporosis and Pagetâ€™s disease. The available evidence from AERS database, Health Canadaâ€™s
Med-effect database and literature review does not suggest an alteration in risk: benefit balance of calcitonin nasal spray.
However acknowledging the limitations of the data and in view of the regulatory authorities review and findings of increased
risk of cancer in uses of calcitonin nasal spray in postmenopausal women. The report establishes the safety of Calcitonin nasal
spray under its recommended conditions of use</Abstract><Email>krishnan_kiran@hotmail.com</Email><articletype>Research</articletype><volume>5</volume><issue>4</issue><year>2014</year><keyword>Benefit-Risk Assessment,Calcitonin Nasal Spray, Calcitonin Salmon,Osteoporosis,Postmenopausal Women</keyword><AUTHORS>Kiran Krishnan,Kathiresan Krishnasamy</AUTHORS><afflication>Department of Pharmacy, Annamalai University, Chidambaram, Tamil Nadu, India,Department of Pharmacy, Annamalai University, Chidambaram, Tamil Nadu, India</afflication></Article></Articles>